1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Axonics, Inc.

Axonics, Inc.

AXNX
Axonics, Inc.US flagNASDAQ Global Select
70.98
USD
- -
- -
3.63BMarket Cap
Axonics, Inc.
AXNX
(NASDAQ Global Select)

Recent

price

70.98

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
TTM
FRC
- -
0.01
0.1
0.48
3.02
4.19
5.86
7.46
8.58
Revenue per Share
-0.95
-0.97
-4.64
-2.8
-1.48
-1.86
-1.28
-0.12
-0.11
Basic EPS, GAAP
-0.96
-1.03
-4.66
-2.97
-2.34
-1.15
0.02
-0.11
0.11
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-2.67
-3.61
-14.24
-6.29
-6.34
-7.3
-8.02
-7.75
-7.8
Book Value per Share
-2.01
-1.93
20.41
6.4
7.77
6.28
8.34
9.31
9.56
Tangible Book Value per Share
18
19
7
29
37
43
47
49
50
Basic Weighted Avg Shares
- -
- -
1
14
112
180
274
366
432
Sales/Revenue/Turnover
- -
-14,198.44
-4,545.54
-583.21
-48.2
-35.86
-15.49
-1.29
-1.67
Operating Margin (%)
1
1
1
1
2
9
12
12
12
Depreciation Expense
-17
-18
-32
-80
-55
-80
-60
-6
-6
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
17.39
Effective Tax Rate (%)
- -
-14,110.16
-4,594.48
-578.4
-49.24
-44.41
-21.81
-1.66
-1.31
Profit Margin (%)
7
25
159
200
282
294
400
446
461
Working Capital
- -
- -
23
25
9
9
8
26
30
LT Debt
-36
-35
143
183
287
482
570
638
664
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
0.4
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Sep'24
ST Debt
1
2
3
LT Borrowings
- -
- -
- -
LT Finance Leases
30
30
30
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
51
51
51
Market Capitalization
3,425
3,355
3,505

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Sep'24
Total Current Assets
482
512
526
Cash, Cash Equivalents & STI
333
343
345
Accounts Receivable, Net
51
57
63
Inventories
93
105
114
Total Current Liabilities
48
57
64
Payables & Accruals
31
30
26
ST Debt
1
2
3
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
36.53%
11.83%
Free Cash Flow
- -
-131.48%
-675%
Net Income, GAAP
- -
9.07%
-89.8%
Sales/Revenue/Turnover
- -
541.82%
33.86%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
48
69
70
86
274
2023
71
93
93
110
366
2024
91
115
116
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
-0.5
-0.47
-0.34
0.01
-1.28
2023
-0.19
-0.15
0.08
0.13
-0.12
2024
-0.38
0.14
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Similar Companies
Theraclion S.A. (TCLIF)
Vitrolife AB (publ) (VITR.ST)
New Horizon Health Limited (6606.HK)
Perspective Therapeutics, Inc. (CATX)
Artivion, Inc. (CRY)
Implanet S.A. (ALIMP.PA)
Business
Axonics, Inc. (NASDAQ: AXNX) develops and commercializes innovative sacral neuromodulation devices for the treatment of bladder and bowel dysfunction. The company offers the Axonics r15™ System, a rechargeable sacral neuromodulation device featuring MRI-compatible leads and a small, long-lasting implantable neurostimulator with up to 15 years of battery life; the Axonics F15™ System, a recharge-free sacral neuromodulation platform designed for patient convenience with five-year battery longevity; and related physician and patient mobile applications for remote monitoring and therapy management. Axonics primarily serves urologists, urogynecologists, and colorectal specialists treating patients with overactive bladder, urinary retention, and fecal incontinence in the United States, Europe, and select international markets. Founded in 2013 and headquartered in Irvine, California, the company focuses on the medtech segment of the healthcare industry, emphasizing minimally invasive therapies for chronic pelvic floor disorders. In recent developments, Axonics continues to expand its commercial footprint following FDA approvals for its second-generation systems and ongoing clinical studies supporting broader indications.

Company News

APIChatGPT

  • zacks.com

    Boston Scientific Stock Set to Gain From Completion of Axonics Deal

  • prnewswire.com

    Boston Scientific Closes Acquisition of Axonics, Inc.

  • zacks.com

    Axonics Modulation Technologies (AXNX) Q3 Earnings and Revenues Top Estimates

  • zacks.com

    Axonics Shares Fall Despite Australia's Approval for R20 SNM Device

  • businesswire.com

    Axonics Receives Regulatory Approval for Fourth-Generation Rechargeable SNM System in Australia

  • zacks.com

    Axonics Stock Rises on Favorable Verdict in Patent Case With Medtronic

  • businesswire.com

    Axonics Prevails in Patent Infringement Lawsuit with Medtronic

  • zacks.com

    Axonics Modulation Technologies (AXNX) Surpasses Q2 Earnings and Revenue Estimates

  • https://www.defenseworld.net

    Axonics, Inc. (NASDAQ:AXNX) Shares Sold by Amalgamated Bank

  • businesswire.com

    Axonics Receives Regulatory Approval for Recharge-Free SNM System in Australia

  • businesswire.com

    Axonics Reports First Quarter 2024 Financial Results

  • prnewswire.com

    Boston Scientific Announces Results for First Quarter 2024

  • reuters.com

    FTC seeks more information on Boston Scientific's $3.7 bln Axonics deal

  • zacks.com

    All You Need to Know About Axonics (AXNX) Rating Upgrade to Buy

  • businesswire.com

    Axonics Stockholders Approve Merger Agreement with Boston Scientific

  • businesswire.com

    Axonics Provides Update on Inter Partes Review Proceedings

  • zacks.com

    Axonics (AXNX) Gets CE Mark for Sacral Neuromodulation System

  • businesswire.com

    Axonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System

  • businesswire.com

    Axonics Responds to ITC Action by Medtronic

  • zacks.com

    Axonics Modulation Technologies (AXNX) Q4 Earnings and Revenues Surpass Estimates